Bajaj Healthcare Share Price
323.80-1.40 (-0.43%)
-23.57% past 1 Year
News
Bajaj Healthcare Q1 EBITDA rises year-on-year with improved margin profile
Equity
BAJAJHCARE
Bajaj Healthcare Q1 FY earnings show healthy year-on-year revenue growth trend
Equity
BAJAJHCARE
Bajaj Healthcare Q1 standalone net profit rises 16 percent year-on-year
Equity
BAJAJHCARE
Bajaj Healthcare schedules Q1 FY2026 earnings conference call on July 21
Equity
BAJAJHCARE
Bajaj Healthcare co-promoter increases stake via open market share purchase
Equity
BAJAJHCARE
Bajaj Healthcare Q4 FY Net Loss Widens to Rs 19.40 Crores vs Profit of Rs 11.20 Crores YoY
Equity
BAJAJHCARE
Bajaj Healthcare reports Profit after tax of Rs -19.41 Crores, in the March 2026 quarter
Equity
BAJAJHCARE
Bajaj Healthcare submits board meeting intimation
Equity
BAJAJHCARE
Bajaj Healthcare informs about disclosure
Equity
BAJAJHCARE
Bajaj Healthcare informs about disclosure
Equity
BAJAJHCARE
Bajaj Healthcare informs about disclosure
Equity
BAJAJHCARE
Bajaj Healthcare informs about board meeting
Equity
BAJAJHCARE
Bajaj Healthcare informs about scrutinizer’s report
Equity
BAJAJHCARE
Bajaj Healthcare - Quaterly Results
Equity
BAJAJHCARE
Bajaj Healthcare Reappoints Sajankumar Bajaj as Chairman and Managing Director.
Equity
BAJAJHCARE
Bajaj Healthcare Q3 FY26 EBITDA Rises 42% YoY to Rs 30.70 Crores with Margin Expansion.
Equity
BAJAJHCARE
Bajaj Healthcare Q3 FY26 Results: Revenue Growth 31% YoY, PAT Surges 7% YoY
Equity
BAJAJHCARE
Bajaj Healthcare reports Profit after tax of 16.10 Crores, in the December 2025 quarter
Equity
BAJAJHCARE
Bajaj Healthcare rises on getting nod to conduct Clinical Trial, Bioequivalence Study of Suvorexant Tablets
Equity
BAJAJHCARE
Bajaj Healthcare Receives CDSCO SEC Recommendation for Phase III Trials of Suvorexant Tablets.
Equity
BAJAJHCARE